Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

912 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial.
Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group. Umemoto S, et al. Among authors: saruta t. Hypertens Res. 2017 Apr;40(4):376-384. doi: 10.1038/hr.2016.158. Epub 2016 Dec 1. Hypertens Res. 2017. PMID: 27904156 Free PMC article. Clinical Trial.
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T; CASE-J Trial Group. Ogihara T, et al. Among authors: saruta t. Hypertens Res. 2008 Aug;31(8):1595-601. doi: 10.1291/hypres.31.1595. Hypertens Res. 2008. PMID: 18971535
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Saito I, Shimada K; COLM study investigators. Ogihara T, et al. Among authors: saruta t. Hypertens Res. 2009 Feb;32(2):163-7. doi: 10.1038/hr.2008.31. Epub 2009 Jan 23. Hypertens Res. 2009. PMID: 19262477 Clinical Trial.
Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial.
Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Yasuno S, Oba K, Takeda K, Higaki J, Nakao K; CASE-J trial Group. Ogihara T, et al. Among authors: saruta t. Hypertens Res. 2009 Apr;32(4):248-54. doi: 10.1038/hr.2008.34. Hypertens Res. 2009. PMID: 19347033 Clinical Trial.
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.
Ogihara T, Saruta T, Shimada K, Kuramoto K. Ogihara T, et al. Among authors: saruta t. Hypertens Res. 2009 Dec;32(12):1148-54. doi: 10.1038/hr.2009.163. Epub 2009 Oct 9. Hypertens Res. 2009. PMID: 19816505 Clinical Trial.
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study.
Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Ogihara T, et al. Among authors: saruta t. Hypertension. 2010 Aug;56(2):196-202. doi: 10.1161/HYPERTENSIONAHA.109.146035. Epub 2010 Jun 7. Hypertension. 2010. PMID: 20530299 Clinical Trial.
912 results